BioMarin Pharmaceutical (BMRN) Stock
Key stats
- Market cap
- $11.30B
- Price / Earnings ratio
- -578.9x
- EPS (TTM)
- -$0.09
- Volume
- Loading
- 52-week high
- $70.98
- 52-week low
- $49.26
- EPS vs analyst estimate
- -76.5%Q3 FY25 · $0.12 vs $0.51
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with BMRN
Recent news

BioMarin Pharmaceutical Q3 Earnings Call Highlights
BioMarin Pharmaceutical Q3 Earnings Call Highlights
BMRN

BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
BMRN

BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates
BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates
BMRN

Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking
Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking
BMRN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 54.64
- MACD 12/26/9
- -0.29
- EMA 9 of MACD
- -0.68
- MACD histogram
- 0.40
- SMA 50
- $59.25
- Price below SMA 50
- EMA 50
- $58.36
- Price below EMA 50
- SMA 200
- $58.46
- Price below SMA 200
- EMA 200
- $58.12
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 12 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.14 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

BioMarin Pharmaceutical Q3 Earnings Call Highlights
BioMarin Pharmaceutical Q3 Earnings Call Highlights
BMRN

BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
BMRN

BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates
BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates
BMRN

Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking
Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking
BMRN

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?
BMRN

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
BMRN

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
BMRN

BioMarin reports five-year Pompe disease data showing durable motor function
BioMarin reports five-year Pompe disease data showing durable motor function
BMRN

Profluent Partners With BioMarin to Design Novel Medicines Using AI
Profluent Partners With BioMarin to Design Novel Medicines Using AI
BMRN

BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone
BMRN
News tone: automated (AI) classification of the article's content, not a price prediction.
About BioMarin Pharmaceutical
BioMarin is a world leader in developing and commercializing therapies for rare genetic diseases. We take pride in going where the science leads us, pioneering breakthrough treatments for debilitating and life-threatening conditions where we can significantly improve upon the current standard of care.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Alexander Hardy | President, CEO & Director | 1969 |
| Mr. Brian R. Mueller CPA | CFO & Executive VP of Finance | 1974 |
| Dr. C. Greg Guyer Ph.D. | Executive VP & CTO | 1962 |
| Ms. Cristin Hubbard | Executive VP & Chief Commercial Officer | — |
| Dr. Gregory Friberg M.D. | Executive VP and Chief Research & Development Officer | — |
| Ms. Rashmi Eshwar Ramchandani | VP, Chief Accounting Officer & Principal Accounting Officer | 1979 |
| Dr. Kevin Eggan Ph.D. | Chief Scientific Officer & Senior VP of Research and Early Development | — |
| Mr. Arpit Dave | Executive Vice President, Chief Digital & Information Officer | — |
| Mr. George Eric Davis J.D. | Executive VP, Chief Legal Officer & Secretary | 1971 |
| Ms. Cara Bauer Ph.D. | Executive VP & Chief People Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 54.64
- MACD 12/26/9
- -0.29
- EMA 9 of MACD
- -0.68
- MACD histogram
- 0.40
- SMA 50
- $59.25
- Price below SMA 50
- EMA 50
- $58.36
- Price below EMA 50
- SMA 200
- $58.46
- Price below SMA 200
- EMA 200
- $58.12
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
12 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $60.00
- Average
- $88.83
- High
- $119.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +5.1 | +4.6 | ||||||||||
| 2022 | -0.8 | -12.7 | -0.3 | +2.6 | -9.8 | +11.4 | +1.3 | +4.4 | -6.7 | -0.1 | +16.6 | +0.5 |
| 2023 | +14.7 | -14.7 | -3.7 | -0.6 | -10.4 | -1.8 | +2.4 | +2.7 | -4.9 | -6.5 | +8.4 | +4.3 |
| 2024 | -10.2 | -2.8 | +0.2 | -7.3 | -9.9 | +7.7 | +2.7 | +7.8 | -23.3 | -6.0 | -0.9 | +1.1 |
| 2025 | -4.7 | +14.0 | -0.5 | -6.3 | -7.4 | -3.6 | +3.0 | +0.2 | -8.3 | -2.4 | +5.8 | +8.0 |
| 2026 | -4.9 | +6.5 | -5.4 | -5.8 | +6.0 | +4.0 | +3.8 | +8.7 | -7.5 | +0.1 | +1.5 |



